Clinical trials
Bone Cancer Metastatic clinical trials
Below are recruiting bone cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT06391242RecruitingPhase 3
Comparing radiation treatments for painful bone metastases
This trial compares two types of radiation therapy—standard palliative radiation and a more targeted high-dose treatment (SBRT)—to see which better relieves pain from bone metastases that have spread outside the spine. It is for people with solid tumors who have a painful bone spot and are expected to live at least 6 months.
Calgary, AlbertaAges 18 years+ - NCT05825456Recruiting
Study of surgery for broken bones from metastatic cancer
This trial looks at outcomes after surgery to stabilize a broken bone caused by cancer that has spread (metastatic cancer). It may help by improving how doctors plan and measure results after specific types of bone stabilization surgery.
Ankara, altindagAges Any age - NCT06571734RecruitingPhase 2
XL092 for advanced sarcoma types
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
Chicago, IllinoisAges 18 years+ - NCT07084571Recruiting
Testing Tissue Sampling Over Time in Advanced Breast Cancer
This study is testing whether it is safe and practical to take multiple small tissue samples (biopsies) from different sites of your breast cancer over time. The goal is to learn how breast cancer changes as it grows, which could help doctors develop better treatments.
LondonAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Long Beach, CaliforniaAges 18 years+ - NCT06321679Recruiting
Study of bone scans for advanced prostate cancer treatment
This trial is testing how well treatments for advanced prostate cancer that has spread to the bones can be seen on scans. It may help doctors find better ways to measure if the cancer is responding to treatment.
MilanAges 18 years+ - NCT06202248Recruiting
DaRT radiation therapy for prostate cancer that has returned
This trial tests a new type of radiation using tiny alpha-emitting seeds placed directly into the tumor. It is for people whose prostate cancer came back in the gland after initial treatment but hasn't spread elsewhere.
HaifaAges 18–120 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Scottsdale, ArizonaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT05963490RecruitingPhase 2
Regorafenib with or without targeted immunotherapy and radiation for spread colon cancer
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
ShanghaiAges 18–70 - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06525428RecruitingPhase 2
Adding radiation and immunotherapy to standard care for advanced colorectal cancer
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT06582628RecruitingPhase 2
Talazoparib and enzalutamide after abiraterone in prostate cancer
This trial tests two drugs—talazoparib and enzalutamide—given together to men whose metastatic prostate cancer has worsened after treatment with abiraterone (Zytiga). The goal is to see if this combination can help control the cancer.
Badalona, BarcelonaAges 18 years+ - NCT06859775RecruitingPhase 1/Phase 2
SHR-A1811 combination for recurrent or metastatic cervical cancer
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
Beijing, Beijing MunicipalityAges 18–75 - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06383767RecruitingPhase 3
A study of ESG401 for advanced HR+/HER2- breast cancer
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
New Haven, ConnecticutAges 18 years+
Hear when a new Bone Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone cancer metastatic?
- Yes. Clin2 currently lists 741 recruiting bone cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.